文献速递基础与转化研究新药、器械与细胞基因治疗研发

靶向蛋白转运调节因子MOG1的基因治疗在Brugada综合征、心律失常及轻度心肌病小鼠模型中的作用

Gene therapy targeting protein trafficking regulator MOG1 in mouse models of Brugada syndrome, arrhythmias, and mild cardiomyopathy.
PubMed 文献 · Sci Transl Med · 2022-06-08

研究构建了Scn5aG1746R/+敲入小鼠Brugada综合征模型,表现出J波、室性心动过速、癫痫和猝死。采用AAV9载体递送MOG1基因治疗,可增加NaV1.5细胞表面表达和心室钠电流,逆转Kcnd3和Cacna1c表达上调,使动作电位异常正常化,消除J波并阻断室性心动过速;在SCN5A p.D1275N人源化敲入小鼠中也 rescue 了心律失常和收缩功能障碍。

要点

  • Scn5aG1746R/+敲入小鼠重现Brugada综合征的J波、室性心动过速、癫痫和猝死。
  • AAV9-MOG1基因治疗增加NaV1.5膜表达和心室钠电流,逆转Kcnd3和Cacna1c上调。
  • 基因治疗使动作电位异常正常化、消除J波并阻断室性心动过速。

核心结论

  • AAV9-MOG1基因治疗可改善Scn5aG1746R/+小鼠的Brugada综合征表型,并在SCN5A p.D1275N人源化敲入小鼠中 rescue 心律失常和收缩功能障碍。
  • 使用小分子伴侣蛋白可能对靶向超过AAV载体容量的大致病基因具有广泛意义。

研究设计与样本

  • 研究生成Scn5aG1746R/+敲入小鼠模型,并采用AAV9载体介导MOG1递送进行基因治疗。
  • 另在携带SCN5A p.D1275N突变的杂合人源化敲入小鼠中评估基因治疗对心律失常和收缩功能障碍的作用。

主要发现

  • 杂合Scn5aG1746R/+敲入小鼠表现出心电图ST段异常(显著J波)、自发性室性心动过速、癫痫和猝死。
  • 室性心动过速由动作电位时程缩短和晚期3相早期后除极引起,与钠电流密度降低及Kcnd3和Cacna1c表达增加相关。
  • AAV9-MOG1基因治疗增加NaV1.5细胞表面表达和心室钠电流,逆转Kcnd3和Cacna1c表达上调,使心脏动作电位异常正常化,消除J波并阻断室性心动过速。
  • 基因治疗还 rescue 了SCN5A p.D1275N杂合人源化敲入小鼠的心律失常和收缩功能障碍表型。

关键数值与推荐

  • Brugada综合征在高发地区估计占所有猝死的4%。
  • SCN5A编码心脏钠通道NaV1.5,导致25%至30%的Brugada综合征病例。
  • SCN5A编码序列长6048碱基对,超过AAV载体的包装容量,因此选择MOG1进行基因治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brugada syndrome (BrS) is a fatal arrhythmia that causes an estimated 4% of all sudden death in high-incidence areas. SCN5A encodes cardiac sodium channel NaV1.5 and causes 25 to 30% of BrS cases. Here, we report generation of a knock-in (KI) mouse model of BrS (Scn5aG1746R/+). Heterozygous KI mice recapitulated some of the clinical features of BrS, including an ST segment abnormality (a prominent J wave) on electrocardiograms and development of spontaneous ventricular tachyarrhythmias (VTs), seizures, and sudden death. VTs were caused by shortened cardiac action potential duration and late phase 3 early afterdepolarizations associated with reduced sodium current density (INa) and increased Kcnd3 and Cacna1c expression. We developed a gene therapy using adeno-associated virus serotype 9 (AAV9) vector-mediated MOG1 delivery for up-regulation of MOG1, a chaperone that binds to NaV1.5 and traffics it to the cell surface. MOG1 was chosen for gene therapy because the large size of the SCN5A coding sequence (6048 base pairs) exceeds the packaging capacity of AAV vectors. AAV9-MOG1 gene therapy increased cell surface expression of NaV1.5 and ventricular INa, reversed up-regulation of Kcnd3 and Cacna1c expression, normalized cardiac action potential abnormalities, abolished J waves, and blocked VT in Scn5aG1746R/+ mice. Gene therapy also rescued the phenotypes of cardiac arrhythmias and contractile dysfunction in heterozygous humanized KI mice with SCN5A mutation p.D1275N. Using a small chaperone protein may have broad implications for targeting disease-causing genes exceeding the size capacity of AAV vectors.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Yu G, Chakrabarti S, Tischenko M, et al. Gene therapy targeting protein trafficking regulator MOG1 in mouse models of Brugada syndrome, arrhythmias, and mild cardiomyopathy. Sci Transl Med. 2022. PMID: 35675436. doi:10.1126/scitranslmed.abf3136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。